Grip strength is emerging as a surprisingly powerful window into human health, and researchers are asking whether the simple test could also help track the effects of experimental therapies aimed at aging.

A handshake may reveal more about aging than meets the eye.

For years, researchers have used handgrip strength as a convenient measure of physical function. Studies involving hundreds of thousands and in some analyses, millions of people have consistently found that weaker grip strength is associated with higher risks of mortality, disability and other adverse health outcomes.

The finding is particularly interesting because grip strength appears to tell researchers something that muscle size alone does not.

In one major study of older adults, muscle strength was strongly associated with mortality even after accounting for muscle size and other factors. The researchers concluded that strength may provide information about muscle quality and overall function, rather than simply the amount of muscle a person has.

That distinction could become increasingly important as scientists investigate experimental therapies designed to modify aspects of aging.

The gene-therapy question

A growing number of experimental gene-therapy approaches are being investigated for their potential effects on muscle, metabolism, vascular function, cellular stress responses and other biological processes associated with aging.

Among the genes attracting attention are follistatin, Klotho, FOXO3, hTERT, SIRT1, PGC-1α, VEGF and FGF21, each associated with different biological pathways.

The approaches are still experimental, and the evidence for their effectiveness as longevity treatments remains limited. Some procedures have also been offered through clinics operating outside the conventional U.S. and European regulatory systems, raising additional questions about safety, evidence and long-term monitoring.

For researchers and clinicians, this creates a fundamental measurement problem:

How do you know whether a therapy that changes a biological process actually makes a person functionally healthier?

Grip strength could provide one practical piece of that puzzle.

More muscle does not always mean more strength

One of the most intriguing issues involves therapies intended to increase muscle growth.

Follistatin, for example, is associated with anabolic effects and has been investigated for its potential to increase muscle tissue. But adding muscle does not necessarily mean adding an equivalent amount of functional strength.

The reason may lie partly in the neuromuscular junction (NMJ), the critical connection through which nerves activate muscle fibers.

As people age, changes in the nervous system and neuromuscular connections can impair the ability of muscles to generate force. Consequently, muscle mass and muscle strength can change at different rates.

This creates a potential problem for evaluating a muscle-building therapy.

A person could gain measurable muscle mass while experiencing a much smaller improvement in functional strength.

In other words, bigger muscles do not automatically mean stronger muscles.

Why this matters for aging research

This phenomenon is sometimes described as biomarker decoupling: a treatment changes one biological measure without producing a corresponding change in another measure that normally tracks with it.

That is particularly important in longevity research.

A biomarker that accurately reflects ordinary aging may not necessarily behave the same way when a therapy deliberately changes one component of the aging process.

For example, a treatment could increase muscle mass without repairing age-related problems in the nervous system. Another therapy could affect metabolism or vascular function without producing an immediate change in muscle strength.

This means researchers may need to look at several measurements at once, rather than relying on a single indicator of biological age.

A surprisingly simple test

One reason grip strength is attractive is its simplicity.

A handheld dynamometer can measure grip force in seconds. The test is inexpensive, non-invasive and easy to repeat over time.

Research has already established a strong association between grip strength and mortality. A 2022 systematic review and meta-analysis covering 48 studies and more than 3.1 million participants found an inverse relationship between grip strength and all-cause mortality, meaning that higher grip strength was generally associated with lower mortality risk.

But there is an important caveat: these studies are primarily observational. They show that grip strength is associated with health outcomes; they do not prove that increasing grip strength itself will extend someone’s life.

That distinction becomes especially important when evaluating experimental longevity therapies.

From aging marker to treatment-response measure?

The next challenge is determining whether grip strength can do more than predict health outcomes.

Researchers are interested in whether repeated measurements could help show how an individual responds to an intervention.

If a therapy produces an increase in muscle mass but little change in grip strength, that could suggest that additional aspects of physical function remain limiting.

Conversely, improvements in strength could provide evidence that changes in muscle or other biological systems are translating into measurable functional benefits, although such a result would still need to be interpreted alongside other clinical and biological measurements.

The latest thinking therefore treats grip strength not as a definitive “aging clock,” but as a systems-level functional biomarker.

It reflects the combined performance of muscles, nerves, neuromuscular connections and the body’s ability to produce force.

The bigger picture

The debate over grip strength points to a larger issue confronting the rapidly developing field of longevity medicine.

Scientists are becoming increasingly capable of targeting individual biological pathways associated with aging. But measuring whether those interventions actually improve human health is considerably more difficult.

A useful aging biomarker must do more than change on a laboratory test. Ideally, it should reflect meaningful improvements in how the body functions.

Grip strength could be one such measure.

It is certainly not a complete measure of biological age, and it cannot by itself establish that a gene therapy slows or reverses aging. But its strong relationship with physical function and long-term health makes it an intriguing candidate for tracking how experimental interventions affect the human body.

As longevity research moves from observing aging to attempting to modify it, something as simple as squeezing a handgrip may become an unexpectedly valuable way of asking a much bigger question:

Is a biological change actually translating into better human function?